Poloxamer 124 (L44)
Based on 1 Customer Validation
Poloxamer 124 L44 is a block polymer of polyoxyethylene and polyoxypropylene and a hydrophobic surfactant. Poloxamer 124 L44 causes eye irritation and exhibits oral toxicity in albino rats with an LD50 of 5 g/kg. Poloxamer 124 L44 has reversible adverse effects on triglyceride and cholesterol transport in the lymphatic system of rats. Poloxamer 124 L44 can form thermoreversible hydrogels and is used as a food additive and as a drug delivery vehicle in cosmetics, pharmaceuticals, and tissue engineering[1][2][3].
For research use only. We do not sell to patients.
- CAS No.: 9003-11-6
- Molecular Weight:2200 (Average)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 9003-11-6
-
Appearance Solid-Liquid Mixture
-
Molecular Weight 2200 (Average)
-
Color Colorless to off-white
-
SMILES
[Poloxamer 124 (L44)]
-
Synonyms
PEG-PPG-PEG, 2200 (Average)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro:
H2O : ≥ 200 mg/mL
* "≥" means soluble, but saturation unknown.
Protocols
-
3D Hydrogel Synthetic Scaffold Culture
3D hydrogel synthetic scaffold culture embeds cells, spheroids, organoids, or tissue fragments inside a hydrated crosslinked polymer network so that cells receive matrix and cell-cell cues in three dimensions rather than from a flat plastic surface. A literature-supported model protocol is PEG-4MAL hydrogel culture, in which four-arm maleimide-terminated PEG is functionalized with cysteine-containing adhesive peptides such as RGD and crosslinked with protease-degradable peptides such as GPQ-W; this creates a defined, modular scaffold that supports human organoid generation and culture. The readouts are scaffold-supported growth, morphology, lumen formation, budding, viability, proliferation, lineage-marker expression, and matrix-dependent expansion or differentiation; reported assays include transmitted-light imaging, immunofluorescence, in situ hybridization, qRT-PCR, and rheological characterization.
-
Repeated-Dose Oral Toxicity Study
A repeated-dose oral toxicity study evaluates systemic toxic effects after daily oral exposure to a test substance for a defined period, commonly 28 days, 6 weeks, 90 days, or 13 weeks in rodent studies. The readout is generated by integrating mortality, clinical signs, body-weight change, food and water intake, functional or behavioral observations, hematology, serum biochemistry, urinalysis, organ weights, necropsy, and histopathology to identify dose-related adverse effects, target organs, and the no-observed-adverse-effect level (NOAEL).
-
Acute Systemic Toxicity Study
Acute systemic toxicity studies evaluate adverse effects occurring after a single exposure, or repeated exposure within a short acute window, and the main in vivo readouts are mortality, moribund condition, clinical signs, body-weight change, and gross pathological findings; acute oral toxicity methods were developed to replace classical LD50 testing with reduced-animal designs such as fixed-dose procedure, acute toxic class method, and up-and-down procedure. The fixed-dose procedure classifies acute toxicity by administering predefined dose levels and observing evident toxicity rather than using death as the primary endpoint, whereas the acute toxic class method uses sequential groups of three animals per step and the up-and-down procedure doses animals sequentially to estimate an LD50 with fewer animals than conventional LD50 testing.
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Singh-Joy SD, et al., Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27 Suppl 2:93-128. [Content Brief]
[2]. Li Y, et al., Ultra-high-performance liquid chromatography coupled with quadrupole time of flight mass spectrometry method for quantifying polymer poloxamer 124 and its application to pharmacokinetic study. J Sep Sci. 2021 Oct;44(20):3822-3829. [Content Brief]
[3]. Tso P, et al. Effect of hydrophobic surfactant (Pluronic L-81) on lymphatic lipid transport in the rat. Am J Physiol. 1980 Nov;239(5):G348-53. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)